SWAN Investors are pleased to announce an investment in Eyetronic, a medical device company pioneering non-invasive optic nerve stimulation therapy designed to halt and potentially restore vision loss in glaucoma patients.

Eyetronic’s technology uses wearable goggles equipped with embedded electrodes to deliver targeted electrical stimulation to the optic nerve, promoting neuroprotection and neuroregeneration. Unlike conventional treatments that focus on reducing intraocular pressure, Eyetronic directly addresses the underlying neural damage responsible for vision loss.

Clinically validated in Europe, the therapy has been used in over 1,000 patients across thousands of treatment sessions, demonstrating meaningful improvements in visual function for many patients. With regulatory approval already in Europe and ongoing clinical studies in the United States, Eyetronic is advancing a new, non-invasive approach to treating glaucoma and other optic nerve-related conditions.